| Literature DB >> 25347946 |
Zoltán H Endre1, John W Pickering2.
Abstract
FDA approval of the first device to use novel biomarkers of kidney damage to assess risk of acute kidney injury (AKI) potentially brings forward diagnosis of moderate-to-severe AKI to a time frame that could enable early intervention. Although the device awaits greater scrutiny, its approval marks the beginning of a new era.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25347946 DOI: 10.1038/nrneph.2014.198
Source DB: PubMed Journal: Nat Rev Nephrol ISSN: 1759-5061 Impact factor: 28.314